Andreas van Baalen

Dr. Andreas van Baalen

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in Epilepsia
Verified
Journal Article
Closed access
PDF file
ABAndreas van Baalen
Andreas van Baalen
MHMartin Häusler
Martin Häusler
RBRainer Boor
Rainer Boor
ARAxel Rohr
Axel Rohr
JSJürgen Sperner
Jürgen Sperner
GKGerhard Kluger
Gerhard Kluger

21 August 2012 in Neuropediatrics
Verified
Journal Article
Closed access
PDF file
ABAndreas van Baalen
Andreas van Baalen
MHMartin Häusler
Martin Häusler
BPBarbara Plecko-Startinig
Barbara Plecko-Startinig
JSJurgis Strautmanis
Jurgis Strautmanis
SVStefan Vlaho
Stefan Vlaho
CBChristian G. Bien
Christian G. Bien
Febrile infection-related epilepsy syndrome (FIRES) is a severe postinfectious epileptic encephalopathy in previously healthy children and has three phases: the initial phase with a simple febrile infection, a few days later the acute phase characterized by a peracute onset of highly recurrent seizures or refractory status epilepticus often with no more fever and generally without additional neurological features (the classical pure seizure phenotype), and last, the chronic phase with a drug-resistant epilepsy and neuropsychological impairments. FIRES seems to be sporadic and very rare: we estimated the annual incidence in children and adolescents by a prospective hospital-based German-wide surveillance as 1 in 1,000,000. Because of the preceding infection and lacking evidence of infectious encephalitis, an immune-mediated pathomechanism and, therefore, a response to immunotherapies may be involved. To test the hypothesis that antibodies against neuronal structures cause FIRES, we analyzed sera of 12 patients aged 2 to 12 years (median 6 years) and cerebral spinal fluids (CSFs) of 3 of these 12 patients with acute or chronic FIRES. We studied six patients (two including CSF) 1 to 14 weeks (median 3 weeks) and six patients 1 to 6 years (median 3.5 years) after seizure onset. All samples were analyzed for antibodies against glutamate receptors of type N-methyl-D-aspartate (NMDA) and type α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA), gamma-aminobutyric acid (GABA)B-receptors, voltage-gated potassium channel (VGKC)-associated proteins leucin-rich glioma inactivated 1 (LGI1) and contactin-associated protein like 2 (CASPR2), and glutamic acid decarboxylase (GAD) by a multiparametric recombinant immunofluorescence assay employing human embryonic kidney (HEK) cells transfected with cDNAs for the antigens. In addition, indirect immunohistochemistry using rat whole-brain sections was done in three patients. Finally, sera of 10 patients were tested for VGKC complex antibodies by radioimmunoprecipitation assay (RIA). None of the antibody tests were positive in any of the patients. Moreover, steroids, immunoglobulins, and plasmapheresis had no clear effect in the seven patients receiving immunotherapy. The failure of antibody-detection against the known neuronal antigens as well as the ineffectiveness of immunotherapy questions a role for autoantibodies in the epileptogenesis of classical FIRES. As we discuss, other underlying causes need to be considered including the possibility of a mitochondrial encephalopathy.

1 July 2016 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
NLNicolas Lang
Nicolas Lang
MLMax Lange
Max Lange
FSFriedhelm Carl Schmitt
Friedhelm Carl Schmitt
MBMonika Bös
Monika Bös
YWYvonne Weber
Yvonne Weber
USUlrich Stephani
Ulrich Stephani

1 January 2009 in Brain and Development
Verified
Journal Article
Closed access
ABAndreas van Baalen
Andreas van Baalen
USUlrich Stephani
Ulrich Stephani
GKGerhard Kluger
Gerhard Kluger
MHMartin Häusler
Martin Häusler
ODOlivier Dulac
Olivier Dulac

7 September 2023 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Open access
ABAndreas van Baalen
Andreas van Baalen
Febrile infection-related epilepsy syndrome (FIRES) of unknown aetiology is an extremely rare but severe epilepsy syndrome. It is characterized by a nonspecific febrile infection a few days before the onset of super-refractory status epilepticus, followed by refractory epilepsy and high morbidity in previously healthy children and young adults. To date, FIRES is incurable and irreversible. The clinical course may depend more on time than on therapy, while the outcome may depend more on the clinical spectrum than on therapy. Based on a literature search, retrospective data analysis, and personal observations, this review aimed to explore the clinical spectrum and therapeutic options for FIRES to improve outcomes by optimized and more standardized diagnosis and therapy, including adapted immunotherapy and a less aggressive approach to manage seizures, as seizure-freeness is difficult to achieve and, therefore, not the primary goal for cryptogenic FIRES.

18 January 2025 in Epilepsia
Verified
Journal Article
Open access
PEPoul H. Espino
Poul H. Espino
KEKrista Eschbach
Krista Eschbach
LBLeah J. Blank
Leah J. Blank
MCMackenzie Cervenka
Mackenzie Cervenka
EMEyal Muscal
Eyal Muscal
TGTeneille E. Gofton
Teneille E. Gofton
We propose and prioritize important outcome domains that should be considered for future research investigating long‐term outcomes (LTO) after new onset refractory status epilepticus (NORSE). The study was led by the international NORSE Institute LTO Working Group. First, literature describing the LTO of NORSE survivors was identified using a PubMed search and summarized to identify knowledge gaps. Subsequently, a consensus‐building process was performed to prioritize and rank important LTO domains for further research. The prioritization of LTO domains was qualitative, enabling the expert panel to generate ideas, share opinions, and provide reasons for the rankings. A second round took place to allow expansion and agreement regarding specific details for each domain. Outcomes were classified into eight main domains: (1) Function: Neuropsychological, Neurological (other than seizures), and Psychiatric (mood and behavior); (2) Quality of Life; (3) Epilepsy; (4) Nonneurological (medical); (5) Social; (6) Caregiver Burden; (7) Long‐Term Mortality; and (8) Health Care System Impact. In addition, the working group suggested obtaining outcome measures for each domain at 6 months and 1 year after discharge and annually thereafter until stability has been reached. There are no currently established time frames set for when LTO in NORSE begin or plateau, and previously there existed no consensus regarding which LTO should be considered. This consensus process identifies and recommends NORSE LTO domains that should be considered in future research studies to provide more consistent results that can be compared between studies. Survivors of NORSE should be evaluated serially and at fixed points over time to maximize our understanding of the recovery trajectory for all LTO domains. Establishing reliable and standardized data describing LTO (beyond seizures) after NORSE will support discussions with families during the acute stages, prognostication, the development of targeted management strategies for survivors, and future comparative research globally helping to identify biomarkers that may predict LTO.